| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Total income | 0.1 | 0.5 | 0.2 |
| Net profit | -0.0 | -0.1 | -0.0 |
| Operating margin | -0.0% | -20.0% | -0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: PRISMMEDI. Figures extracted from the filing.
Prism Medico and Pharmacy Ltd: key numbers
- Share price
- ₹28.99
- Market cap
- ₹39.32 Cr
- Revenue (annual)
- ₹2.44 Cr
- Net profit (annual)
- ₹0.32 Cr
- P/E (TTM)
- -99.0×Sector 42.2×
- Promoter holding
- 29.98%+4.49% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Prism Medico and Pharmacy Ltd
All →Prism Medico and Pharmacy Management Change
Prism Medico and Pharmacy Limited re-appointed Davender Singh as a Non-Executive Non-Independent Director. The company also updated its statutory and secretarial auditor appointments.
Prism Medico and Pharmacy Annual General Meeting
Prism Medico and Pharmacy held its 24th Annual General Meeting on September 19, 2026, to transact ordinary and special business, including various investment approvals.
Prism Medico and Pharmacy Annual Report
Prism Medico and Pharmacy Limited has filed its Annual Report for the financial year 2025-2026 in accordance with Regulation 34 of SEBI LODR Regulations.
Prism Medico and Pharmacy Annual General Meeting
Prism Medico and Pharmacy Limited has scheduled its 24th Annual General Meeting for September 19, 2026, through video conferencing to transact ordinary and special business.
Prism Medico and Pharmacy Board Meeting Outcome
Prism Medico and Pharmacy's board approved the Director's Report and the 24th AGM notice for September 19, 2026. It also recommended auditor appointments and preferential issue object variation.
Prism Medico and Pharmacy Board Meeting Date
Prism Medico and Pharmacy Limited has scheduled a board meeting on August 24, 2026, to approve the Director's Report and convene the 24th AGM.